Media stories about Abeona Therapeutics (NASDAQ:ABEO) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Abeona Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.0241149553936 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Abeona Therapeutics Appoints Carsten Thiel as Chief Executive Officer (pharmatimes.com)
- ValuEngine Upgrades Abeona Therapeutics (ABEO) to Hold (americanbankingnews.com)
- Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $270,000.00 (americanbankingnews.com)
- BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer (reuters.com)
- New chief at Abeona (seekingalpha.com)
A number of analysts have issued reports on the company. ValuEngine raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. HC Wainwright set a $30.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 21st. Cantor Fitzgerald set a $36.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 20th. Finally, Maxim Group set a $35.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Monday, March 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $28.88.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Abeona Therapeutics had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.24 million. Abeona Therapeutics’s quarterly revenue was down 16.0% on a year-over-year basis. analysts anticipate that Abeona Therapeutics will post -0.79 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3338662/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-abeona-therapeutics-abeo-share-price.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.